IOL Chemicals and Pharmaceuticals Ltd

IOL Chemicals & Pharmaceuticals Ltd share price gained 2.85% to Rs 167.8 after the company's net profit jumped 21.14% to Rs 64.4 crore, while revenue from operations increased sharply by 22.09% to Rs 756.26 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.54 lakh crore, gaining 5.24%. It has marginally improved by 0.74% over last one week and heading higher by 13.39% in last one month while the market capitalization of IOL Chemicals & Pharmaceuticals Ltd has edged up by 10.65% and 58.74% in the same period respectively. Profit before tax (PBT) of IOL Chemicals & Pharmaceuticals Ltd stood at Rs 86.69 crore in Q2 FY26, rallying 90.49% year-on-year, and surging by 22.43% quarter-on-quarter. EBITDA came in at Rs 95 crore, expanding by 74.02% YoY and easing 5.16% sequentially. Total expenses jumped by 23.18% to Rs 674.11 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 506.76 crore, jumping 26.17% YoY, while employee benefits expense was at Rs 71.21 crore, ticking higher by 1.25% YoY. For the TTM ended FY26, revenue from operations softened by 2.51% to Rs 2079.21 crore, while net profit tanked by 24.82% to Rs 101.07 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 20860% to Rs 179.89 crore, and PBT plunged by 24.05% to Rs 137.96 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 178.62 crore in FY26, as against Rs 290.08 crore in FY25. IOL Chemicals & Pharmaceuticals Ltd soared by 71.22% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.63% during the same period.

IOL Chemicals and Pharmaceuticals Limited will hold a board meeting on Monday, August 10, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026, and the trading window for designated persons will remain closed until August 13, 2026, as per SEBI regulations.

IOL Chemicals & Pharmaceuticals announced that the Annual General Meeting(AGM) of the company will be held on 2 September 2026.

Net profit of IOL Chemicals & Pharmaceuticals rose 69.19% to Rs 53.16 crore in the quarter ended March 2026 as against Rs 31.42 crore during the previous quarter ended March 2025. Sales rose 17.37% to Rs 619.45 crore in the quarter ended March 2026 as against Rs 527.78 crore during the previous quarter ended March 2025. For the full year,net profit rose 36.18% to Rs 137.64 crore in the year ended March 2026 as against Rs 101.07 crore during the previous year ended March 2025. Sales rose 11.54% to Rs 2319.06 crore in the year ended March 2026 as against Rs 2079.21 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales619.45527.78 17 2319.062079.21 12 OPM %14.9311.89 -11.609.73 - PBDT91.1063.25 44 275.80209.95 31 PBT70.8144.70 58 195.57137.96 42 NP53.1631.42 69 137.64101.07 36 Powered by Capital Market - Live

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 20 May 2026.

The company has enhanced the manufacturing capacity of Ethyl Acetate from 1,00,000 MT per annum to 1,20,000 MT per annum with a capex of about Rs 4 crore. The additional capacity of 20,000 MTPA was completed on 2 March 2026. The expansion has been undertaken to cater to sustained demand growth across various sectors and to improve margin realisation through optimal operating leverage. In addition, the company has expanded the manufacturing capacity of Acetic Anhydride from 25,000 MTPA to 32,000 MTPA. The project entails a capital expenditure of about Rs 5.71 crore. The existing facility was operating at above 90% capacity utilisation prior to the expansion. The additional capacity of 7,000 MTPA was commissioned on 2 March 2026. This expansion is aimed at optimising captive consumption as well as increasing merchant sales. IOL Chemicals & Pharmaceuticals is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets. The company's consolidated net profit rose marginally by 0.2% to Rs 20.58 crore, while net sales increased 10.9% to Rs 580.39 crore in Q3 FY26 compared with Q3 FY25. The counter dropped 1.77% to Rs 70 on the BSE.Powered by Capital Market - Live

Net profit of IOL Chemicals & Pharmaceuticals rose 0.24% to Rs 20.58 crore in the quarter ended December 2025 as against Rs 20.53 crore during the previous quarter ended December 2024. Sales rose 10.91% to Rs 580.39 crore in the quarter ended December 2025 as against Rs 523.30 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales580.39523.30 11 OPM %9.878.96 - PBDT58.9446.48 27 PBT38.7627.80 39 NP20.5820.53 0 Powered by Capital Market - Live

IOL Chemicals & Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 11 February 2026, inter alia, have recommended the interim dividend of Rs 1 per equity Share (i.e. 50%) , subject to the approval of the shareholders.Powered by Capital Market - Live

IOL Chemicals & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

Net profit of IOL Chemicals & Pharmaceuticals rose 56.50% to Rs 29.97 crore in the quarter ended September 2025 as against Rs 19.15 crore during the previous quarter ended September 2024. Sales rose 7.95% to Rs 567.53 crore in the quarter ended September 2025 as against Rs 525.75 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales567.53525.75 8 OPM %10.067.91 - PBDT60.4843.88 38 PBT40.4925.94 56 NP29.9719.15 57 Powered by Capital Market - Live